PI Trade Names and Active Ingredients containing Arixtra. 1 Documents available. Need more information on a product? Search the Australian Register of. Mylan manufactures ARIXTRA®* (fondaparinux sodium) Injection, Solution ( Arixtra) in strengths of 25 mg05 mL 5 mgmL5 mg04 mL mgmL75 mg06 mL injection of Arixtra mg in young healthy subjects are provided in Table 1 below: . Arixtra mg once daily following hip fracture surgery, patients were.
|Published (Last):||22 April 2004|
|PDF File Size:||17.78 Mb|
|ePub File Size:||16.11 Mb|
|Price:||Free* [*Free Regsitration Required]|
TGA eBS – Product and Consumer Medicine Information
Moderate The concomitant use of ibrutinib and anticoagulant agents such as fondaparinux may increase the risk of bleeding; monitor patients for signs of bleeding. Patients taking ginger and an anticoagulant should be monitored closely for bleeding. In the DVT and PE treatment clinical trials, the risk of fondaparinux-associated major bleeding increased with age: Monitor patients who are taking anticoagulants closely and adjust anticoagulation therapy as necessary. Avoid concurrent use of herbs which interact with warfarin when possible.
Additionally, nandrolone decanoate may generate a pharmacodynamic interaction with warfarin by independently affecting the activity of circulating coagulation proteins. All steps to avoid hematoma formation are recommended. Moderate Because clopidogrel inhibits platelet aggregation, a potential additive risk for bleeding exists if clopidogrel is given in combination with other agents that affect hemostasis such as anticoagulants.
Moderate Because of the potential effects of certain dextran formulations on bleeding time, use with caution in patients on anticoagulants concurrently.
Moderate Caution is advised when administering miltefosine with anticoagulants, as use of these drugs together may increase risk for bleeding. As with other antithrombotic agents, fondaparinux should be used with extreme caution in patients with an increased risk of hemorrhage. Moderate When used concurrently with anticoagulants, treprostinil may increase the risk of bleeding. See Dosage section for specific information on timing of subcutaneous administration. Concomitant treatment with warfarin should be initiated as soon as possible, usually within 72 hours.
Clinical trials are needed to determine if fondaparinux is a safe alternative to heparin in patients at risk for HIT. The causality and mechanism of this potential interaction have not been established.
Since ginkgo produces clinically-significant antiplatelet effects, it should be used cautiously in patients drugs that inhibit platelet aggregation or pose a risk for bleeding, such as anticoagulants e. Moderate Use caution when discontinuing eltrombopag in patients receiving anticoagulants e. Patients receiving oral anticoagulant therapy should be closely monitored, especially when methyltestosterone treatment is initiated or discontinued.
Moderate Caution should be used when administering tipranavir to patients receiving anticoagulants.
Arixtra (fondaparinux sodium) dose, indications, adverse effects, interactions from
Moderate Due to the thrombocytopenic effects of nelarabine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants. Fondaparinux should be used cautiously in patients with a history of heparin-induced thrombocytopenia HIT. In-vitro cross-reactivity with antibodies that produce heparin-induced thrombocytopenia has not been observed.
Major Discontinue rivaroxaban before starting fondaparinux due to the increased bleeding risk, unless these agents are essential. Persons who are receiving anticoagulants should not take kava kava without first discussing use with their health care professional. Monitor pregnant women receiving fondaparinux carefully for evidence of bleeding or unexpected changes arixxtra coagulation parameters.
No further data regarding the safety and efficacy of this route of administration are available. Bleeding rates were similar between the 2 groups. Moderate Concurrent use of topiramate and anticoagulants e. Use of fondaparinux may increase the risk of bleeding in the fetus or neonate; monitor neonates for bleeding. One month later, the patient’s INR was 1. For patients undergoing hip surgery extended DVT prophylaxis is indicated up to 24 additional days; up to a total 32 of arixhra peri-operative and extended prophylaxis has been tolerated during clinical trials.
Additive hematological effects are possible as a result of the platelet inhibitory effects of sulfinpyrazone; the sulfide metabolite of sulfinpyrazone appears responsible for this effect. The injection site should be rotated with each injection. ACCP guidelines recommend fondaparinux as an alternative to the preferred agent, low molecular weight heparin, as antithrombotic prophylaxis for patients undergoing total hip or total knee replacement surgery or hip fracture surgery.
The patient denied noncompliance and other changes in diet, medications, or health.
Umbilical cord plasma fondaparinux concentrations were one-tenth the concentration in maternal plasma. Fondaparinux was administered intravenously for the first dose in the OASIS-6 trial to patients with an indication for heparin therapy e.
Do not administer intramuscularly. A patient with previous INRs of 3. Risk factors include those undergoing surgery with general anesthesia lasting more than 45 minutes who are 1 more than 60 years or 2 more than 40 years with at least 1 of the following: To avoid loss of drug when using the prefilled syringes, do not expel the bubble of air from the syringe before injection.
Moderate lthough anagrelide inhibits platelet aggregation at high doses, there is a potential additive risk for bleeding if anagrelide is given in combination with other agents that effect hemostasis such as other anticoagulants. This route is not FDA-approved. Safe and effective use of fondaparinux in neonates, infants, and children has not been established.
Major Prasterone DHEA is contraindicated for use in patients with active deep vein thrombosis, pulmonary embolism or history of these conditions. Monitor patients for signs and symptoms of bleeding. If used concurrently, monitor patients closely for bleeding at the IM injection site.
Bleeding, endocarditis, epidural anesthesia, GI bleeding, lumbar puncture, spinal anesthesia, stroke, surgery. Careful monitoring of the INR and necessary adjustment of the warfarin dosage are also recommended when the androgen therapy is changed or discontinued.
Patients on anticoagulants should be monitored for changes in response to anticoagulation therapy if cilostazol is administered concurrently. Moderate Because fulvestrant is given intramuscularly, it should not be used or given with caution in patients receiving anticoagulants. Theoretically, fondaparinux should not cause HIT because it does not bind to platelet factor 4. We do not record any personal information entered above.
Adults weight 50 kg or more. Reports of decreased prothrombin, increased INR, and unbalanced anticoagulant treatment resulting in change of hemostatic parameters have been reported in patients treated concomitantly with orlistat and anticoagulants. Discontinue edoxaban before starting fondaparinux, unless these agents are essential.